Document is current
Any future updates will be listed below
-
Authors
Kaneshige, Atsunori https://orcid.org/0000-0001-5956-3009
Bai, Longchuan
Wang, Mi
McEachern, Donna
Meagher, Jennifer L.
Xu, Renqi
Wang, Yu
Jiang, Wei
Metwally, Hoda
Kirchhoff, Paul D.
Zhao, Lijie
Jiang, Hui https://orcid.org/0000-0003-2718-9811
Wang, Meilin https://orcid.org/0000-0003-4509-9561
Wen, Bo https://orcid.org/0000-0002-8337-220X
Sun, Duxin https://orcid.org/0000-0002-6406-2126
Stuckey, Jeanne A. https://orcid.org/0000-0002-4192-8900
Wang, Shaomeng
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA046592, P30CA046592)
- License Information
-
More Information
Article History
Received: 23 March 2022
Accepted: 21 December 2022
First Online: 2 February 2023
Competing interests
: The University of Michigan has filed patent applications on inhibitors and degraders described in this study, which have been licensed to Oncopia Therapeutics, Proteovant Therapeutics and Roivant Sciences. S.W., A.K., L.B. M.W., D.M. and J.S. are co-inventors on one or more of these patent applications and receive royalties from the University of Michigan. The University of Michigan has received a research contract from Oncopia/Proteovant/Roivant, for which S.W. serves as the principal investigator. S.W. is a paid consultant to Proteovant/Roivant and owns equity in Roivant. The remaining authors declare no competing interests.
